Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).

<h4>Background</h4>Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer.<h4>Patients and methods</h4>Formalin-fixed paraffin-embedded tumor blocks were collected from women with early breast cancer...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: George Pentheroudakis, Vassiliki Kotoula, Anastasia G Eleftheraki, Eleftheria Tsolaki, Ralph M Wirtz, Konstantine T Kalogeras, Anna Batistatou, Mattheos Bobos, Meletios A Dimopoulos, Eleni Timotheadou, Helen Gogas, Christos Christodoulou, Kyriaki Papadopoulou, Ioannis Efstratiou, Chrisoula D Scopa, Irene Papaspyrou, Dimitrios Vlachodimitropoulos, Helena Linardou, Epaminontas Samantas, Dimitrios Pectasides, Nicholas Pavlidis, George Fountzilas
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/de7b698a336a489a9dca63a420578ebb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:de7b698a336a489a9dca63a420578ebb
record_format dspace
spelling oai:doaj.org-article:de7b698a336a489a9dca63a420578ebb2021-11-18T09:02:09ZPrognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).1932-620310.1371/journal.pone.0070634https://doaj.org/article/de7b698a336a489a9dca63a420578ebb2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23923010/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer.<h4>Patients and methods</h4>Formalin-fixed paraffin-embedded tumor blocks were collected from women with early breast cancer participating in two HeCOG adjuvant trials. Messenger RNA was studied by quantitative PCR, ER protein expression was centrally assessed using immunohistochemistry (IHC) and ESR1 gene copy number by dual fluorescent in situ hybridization probes.<h4>Results</h4>In a total of 1010 women with resected node-positive early breast adenocarcinoma, the tumoral ESR1/CEP6 gene ratio was suggestive of deletion in 159 (15.7%), gene gain in 551 (54.6%) and amplification in 42 cases (4.2%), with only 30 tumors (3%) harboring five or more ESR1 copies. Gene copy number ratio showed a significant, though weak correlation to mRNA and protein expression (Spearman's Rho <0.23, p = 0.01). ESR1 clusters were observed in 9.5% (57 gain, 38 amplification) of cases. In contrast to mRNA and protein expression, which were favorable prognosticators, gene copy number changes did not obtain prognostic significance. When ESR1/CEP6 gene ratio was combined with function (as defined by ER protein and mRNA expression) in a molecular classifier, the Gene Functional profile, it was functional status that impacted on prognosis. In univariate analysis, patients with functional tumors (positive ER protein expression and gene ratio normal or gain/amplification) fared better than those with non-functional tumors with ESR1 gain (HR for relapse or death 0.49-0.64, p = 0.003). Significant interactions were observed between gene gain/amplification and paclitaxel therapy (trend for DFS benefit from paclitaxel only in patients with ESR1 gain/amplification, p = 0.066) and Gene Functional profile with HER2 amplification (Gene Functional profile prognostic only in HER2-normal cases, p = 0.029).<h4>Conclusions</h4>ESR1 gene deletion and amplification do not constitute per se prognostic markers, instead they can be classified to distinct prognostic groups according to their protein-mediated functional status.George PentheroudakisVassiliki KotoulaAnastasia G EleftherakiEleftheria TsolakiRalph M WirtzKonstantine T KalogerasAnna BatistatouMattheos BobosMeletios A DimopoulosEleni TimotheadouHelen GogasChristos ChristodoulouKyriaki PapadopoulouIoannis EfstratiouChrisoula D ScopaIrene PapaspyrouDimitrios VlachodimitropoulosHelena LinardouEpaminontas SamantasDimitrios PectasidesNicholas PavlidisGeorge FountzilasPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 7, p e70634 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
George Pentheroudakis
Vassiliki Kotoula
Anastasia G Eleftheraki
Eleftheria Tsolaki
Ralph M Wirtz
Konstantine T Kalogeras
Anna Batistatou
Mattheos Bobos
Meletios A Dimopoulos
Eleni Timotheadou
Helen Gogas
Christos Christodoulou
Kyriaki Papadopoulou
Ioannis Efstratiou
Chrisoula D Scopa
Irene Papaspyrou
Dimitrios Vlachodimitropoulos
Helena Linardou
Epaminontas Samantas
Dimitrios Pectasides
Nicholas Pavlidis
George Fountzilas
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
description <h4>Background</h4>Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer.<h4>Patients and methods</h4>Formalin-fixed paraffin-embedded tumor blocks were collected from women with early breast cancer participating in two HeCOG adjuvant trials. Messenger RNA was studied by quantitative PCR, ER protein expression was centrally assessed using immunohistochemistry (IHC) and ESR1 gene copy number by dual fluorescent in situ hybridization probes.<h4>Results</h4>In a total of 1010 women with resected node-positive early breast adenocarcinoma, the tumoral ESR1/CEP6 gene ratio was suggestive of deletion in 159 (15.7%), gene gain in 551 (54.6%) and amplification in 42 cases (4.2%), with only 30 tumors (3%) harboring five or more ESR1 copies. Gene copy number ratio showed a significant, though weak correlation to mRNA and protein expression (Spearman's Rho <0.23, p = 0.01). ESR1 clusters were observed in 9.5% (57 gain, 38 amplification) of cases. In contrast to mRNA and protein expression, which were favorable prognosticators, gene copy number changes did not obtain prognostic significance. When ESR1/CEP6 gene ratio was combined with function (as defined by ER protein and mRNA expression) in a molecular classifier, the Gene Functional profile, it was functional status that impacted on prognosis. In univariate analysis, patients with functional tumors (positive ER protein expression and gene ratio normal or gain/amplification) fared better than those with non-functional tumors with ESR1 gain (HR for relapse or death 0.49-0.64, p = 0.003). Significant interactions were observed between gene gain/amplification and paclitaxel therapy (trend for DFS benefit from paclitaxel only in patients with ESR1 gain/amplification, p = 0.066) and Gene Functional profile with HER2 amplification (Gene Functional profile prognostic only in HER2-normal cases, p = 0.029).<h4>Conclusions</h4>ESR1 gene deletion and amplification do not constitute per se prognostic markers, instead they can be classified to distinct prognostic groups according to their protein-mediated functional status.
format article
author George Pentheroudakis
Vassiliki Kotoula
Anastasia G Eleftheraki
Eleftheria Tsolaki
Ralph M Wirtz
Konstantine T Kalogeras
Anna Batistatou
Mattheos Bobos
Meletios A Dimopoulos
Eleni Timotheadou
Helen Gogas
Christos Christodoulou
Kyriaki Papadopoulou
Ioannis Efstratiou
Chrisoula D Scopa
Irene Papaspyrou
Dimitrios Vlachodimitropoulos
Helena Linardou
Epaminontas Samantas
Dimitrios Pectasides
Nicholas Pavlidis
George Fountzilas
author_facet George Pentheroudakis
Vassiliki Kotoula
Anastasia G Eleftheraki
Eleftheria Tsolaki
Ralph M Wirtz
Konstantine T Kalogeras
Anna Batistatou
Mattheos Bobos
Meletios A Dimopoulos
Eleni Timotheadou
Helen Gogas
Christos Christodoulou
Kyriaki Papadopoulou
Ioannis Efstratiou
Chrisoula D Scopa
Irene Papaspyrou
Dimitrios Vlachodimitropoulos
Helena Linardou
Epaminontas Samantas
Dimitrios Pectasides
Nicholas Pavlidis
George Fountzilas
author_sort George Pentheroudakis
title Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
title_short Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
title_full Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
title_fullStr Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
title_full_unstemmed Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
title_sort prognostic significance of esr1 gene amplification, mrna/protein expression and functional profiles in high-risk early breast cancer: a translational study of the hellenic cooperative oncology group (hecog).
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/de7b698a336a489a9dca63a420578ebb
work_keys_str_mv AT georgepentheroudakis prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT vassilikikotoula prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT anastasiageleftheraki prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT eleftheriatsolaki prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT ralphmwirtz prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT konstantinetkalogeras prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT annabatistatou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT mattheosbobos prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT meletiosadimopoulos prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT elenitimotheadou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT helengogas prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT christoschristodoulou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT kyriakipapadopoulou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT ioannisefstratiou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT chrisouladscopa prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT irenepapaspyrou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT dimitriosvlachodimitropoulos prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT helenalinardou prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT epaminontassamantas prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT dimitriospectasides prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT nicholaspavlidis prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
AT georgefountzilas prognosticsignificanceofesr1geneamplificationmrnaproteinexpressionandfunctionalprofilesinhighriskearlybreastcanceratranslationalstudyofthehelleniccooperativeoncologygrouphecog
_version_ 1718421054104272896